Stay updated on MBG453 Combo in IPSS-R MDS Clinical Trial

Sign up to get notified when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MBG453 Combo in IPSS-R MDS Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The page now shows a glossary toggle and color-coded change highlights (green for additions, red for deletions). The revision badge has been updated to v3.4.0, replacing v3.3.4.
    Difference
    0.4%
    Check dated 2026-01-28T06:17:43.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Version v3.3.4 was added (2026-01-13) with new core content sections Adverse Events, Participant Flow, References, Contacts/Locations, and Study Status; the older Revision: v3.3.3 entry from 2025-11-24 was removed.
    Difference
    0.4%
    Check dated 2026-01-14T02:12:41.000Z thumbnail image
  4. Check
    43 days ago
    Change Detected
    Summary
    Revision: v3.3.3 was added to the page history and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the footer. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-23T09:17:20.000Z thumbnail image
  5. Check
    65 days ago
    Change Detected
    Summary
    Revision updated in the footer from v3.3.1 to v3.3.2. This is a minor site version update and does not affect the study information displayed.
    Difference
    0.0%
    Check dated 2025-12-01T18:00:04.000Z thumbnail image
  6. Check
    72 days ago
    Change Detected
    Summary
    In December 2023, Novartis terminated the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) failed to meet primary objectives. The termination was not due to safety concerns, and the 2025 revision added new sections such as Limitations and Caveats, Adverse Events, Outcome Measures, Baseline Characteristics, and Participant Flow.
    Difference
    0.6%
    Check dated 2025-11-24T15:01:19.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    Removal of a government funding/status notice from the page; no trial record content or navigation is affected.
    Difference
    0.3%
    Check dated 2025-11-17T07:21:51.000Z thumbnail image

Stay in the know with updates to MBG453 Combo in IPSS-R MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MBG453 Combo in IPSS-R MDS Clinical Trial page.